LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Inicio・Lista de Acciones・Vaxart Inc

Vaxart Inc

Cerrado

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave
By Trading Economics
Ingresos	6.8M -8.1M
Ventas	33M 72M
Margen de beneficio	-11.242
Empleados	105
EBITDA	6.7M -5.4M

Dividendos
By Dow Jones
Próximas Ganancias	19 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	101M 192M
Apertura anterior	0
Cierre anterior	0

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

0.4007 / 0.4252 Soporte y Resistencia

Vaxart Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 mar 2026, 21:14 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15 mar 2026, 21:14 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15 mar 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15 mar 2026, 23:44 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15 mar 2026, 23:35 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15 mar 2026, 23:00 UTC

Adquisiciones, fusiones, absorciones

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15 mar 2026, 22:37 UTC

Charlas de Mercado

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15 mar 2026, 22:18 UTC

Charlas de Mercado

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15 mar 2026, 22:00 UTC

Noticias de Eventos Importantes

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 22:00 UTC

Noticias de Eventos Importantes

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 03:00 UTC

Noticias de Eventos Importantes

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14 mar 2026, 15:00 UTC

Noticias de Eventos Importantes

Iran War Delivers Windfall to America's Oil Country -- WSJ

14 mar 2026, 02:03 UTC

Ganancias

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 mar 2026, 01:32 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 mar 2026, 00:29 UTC

Adquisiciones, fusiones, absorciones

13D Filings -- Barrons.com

13 mar 2026, 22:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Adquisiciones, fusiones, absorciones

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Charlas de Mercado

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Noticias de Eventos Importantes

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Comparación entre iguales

Cambio de precio

Vaxart Inc Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Vaxart Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.4007 / 0.4252Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.